Clinical Trials
11 trialsNCT01174121 2026-06-05
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT03412877 2026-05-29
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT04102436 2024-03-12
Non-Viral TCR Gene Therapy
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT01967823 2021-03-24
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00784524 2019-06-06
Phase II Study of Allo LMI Vaccine With IL-2 for Stable Metastatic Breast Ca
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT00003199 2017-07-12
Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00006228 2013-10-08
Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00019084 2013-06-20
Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00003408 2013-03-26
Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00935558 2012-05-31
Dendritic Cell Based Therapy for Breast Cancer Patients
Herlev Hospital
Phase 2 Withdrawn
NCT00003125 2011-03-24
Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors
Georgetown University
Phase 2 Completed